Opinion

Video

EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Author(s):

Lawrence Karsh, MD, FACS,Stephen J. Freedland, MD

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Related Videos
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Related Content
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke
Initial study results may be available as soon as the first half of 2026.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Stephen J. Freedland, MD
April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor
More than 80% of patients in both groups had a full recovery of testosterone.
Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell
Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
© 2025 MJH Life Sciences

All rights reserved.